JP2006501181A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501181A5
JP2006501181A5 JP2004518651A JP2004518651A JP2006501181A5 JP 2006501181 A5 JP2006501181 A5 JP 2006501181A5 JP 2004518651 A JP2004518651 A JP 2004518651A JP 2004518651 A JP2004518651 A JP 2004518651A JP 2006501181 A5 JP2006501181 A5 JP 2006501181A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
substituted
phenyl
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004518651A
Other languages
English (en)
Japanese (ja)
Other versions
JP4541882B2 (ja
JP2006501181A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/007005 external-priority patent/WO2004005248A1/en
Publication of JP2006501181A publication Critical patent/JP2006501181A/ja
Publication of JP2006501181A5 publication Critical patent/JP2006501181A5/ja
Application granted granted Critical
Publication of JP4541882B2 publication Critical patent/JP4541882B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004518651A 2002-07-02 2003-07-01 Smacタンパク質のアポトーシスタンパク質阻害物質(iap)との結合に対するペプチド阻害剤 Expired - Fee Related JP4541882B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39315002P 2002-07-02 2002-07-02
PCT/EP2003/007005 WO2004005248A1 (en) 2002-07-02 2003-07-01 Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)

Publications (3)

Publication Number Publication Date
JP2006501181A JP2006501181A (ja) 2006-01-12
JP2006501181A5 true JP2006501181A5 (https=) 2006-08-31
JP4541882B2 JP4541882B2 (ja) 2010-09-08

Family

ID=30115550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004518651A Expired - Fee Related JP4541882B2 (ja) 2002-07-02 2003-07-01 Smacタンパク質のアポトーシスタンパク質阻害物質(iap)との結合に対するペプチド阻害剤

Country Status (8)

Country Link
US (2) US20060128632A1 (https=)
EP (1) EP1519918A1 (https=)
JP (1) JP4541882B2 (https=)
CN (1) CN100384819C (https=)
AU (1) AU2003249920A1 (https=)
BR (1) BR0312408A (https=)
CA (1) CA2491041A1 (https=)
WO (1) WO2004005248A1 (https=)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291615B2 (en) 2003-05-01 2007-11-06 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
EP1715882A4 (en) * 2004-01-16 2009-04-08 Univ Michigan SMAC-PEPTIDOMIMETIKA AND ITS USES
CN1953744A (zh) * 2004-02-05 2007-04-25 诺瓦提斯公司 Dna拓扑异构酶抑制剂和iap抑制剂的组合
AU2005228950B2 (en) * 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
DK2253614T3 (da) * 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
KR100984459B1 (ko) 2004-07-02 2010-09-29 제넨테크, 인크. Iap의 억제제
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
DK1836201T4 (da) * 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
MX2007010371A (es) 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
DE102005017116A1 (de) * 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Birドメイン結合化合物
WO2006128455A2 (en) 2005-05-25 2006-12-07 2Curex Aps Compounds modifying apoptosis
US8318717B2 (en) 2005-05-25 2012-11-27 2Curex Compounds modifying apoptosis
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) * 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
CN101374829A (zh) 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
KR20080080131A (ko) 2005-12-20 2008-09-02 노파르티스 아게 Iap-억제제와 탁산의 조합물
UA96283C2 (uk) * 2005-12-23 2011-10-25 Зіланд Фарма А/С Модифіковані міметики лізину
TWI504597B (zh) * 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
WO2008014229A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Iap阻害剤
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
MX2009000824A (es) * 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008045905A1 (en) 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
AU2007325280B2 (en) 2006-11-28 2011-03-10 Dana-Farber Cancer Institute, Inc. Combination of IAP inhibitors and FLT3 inhibitors
NZ577150A (en) 2006-12-19 2012-04-27 Genentech Inc Imidazopyridine inhibitors of iap
EP2074087A2 (en) 2006-12-21 2009-07-01 Wyeth Synthesis of pyrrolidine compounds
JP5454943B2 (ja) * 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク. 抗癌剤として有用なsmac模倣二量体及び三量体
WO2008134679A1 (en) 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法
AU2009203971A1 (en) * 2008-01-11 2009-07-16 Genentech, Inc. Inhibitors of IAP
JP2011529962A (ja) 2008-08-02 2011-12-15 ジェネンテック, インコーポレイテッド Iapのインヒビター
US20110218211A1 (en) * 2008-08-16 2011-09-08 Genentech, Inc. Azaindole inhibitors of iap
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US20110034469A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Heterocyclic Compound
CN105646471A (zh) 2009-08-12 2016-06-08 诺华股份有限公司 细胞凋亡蛋白抑制剂的固体口服制剂和晶形
EP2478358A1 (en) * 2009-09-18 2012-07-25 Novartis AG Biomarkers for iap inhibitor compounds
CN102050867A (zh) * 2009-11-10 2011-05-11 上海艾力斯医药科技有限公司 四肽类似物、制备方法及其应用
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
GB201506872D0 (en) * 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
BR112017028269A2 (pt) * 2015-07-13 2018-09-04 Arvinas Inc composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. Egfrタンパク質分解標的化キメラ分子およびその関連する使用方法
KR20250117470A (ko) 2016-12-23 2025-08-04 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
BR112019015312A2 (pt) 2017-01-26 2020-03-10 Arvinas Operations, Inc. Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
CN110709096B (zh) 2017-05-05 2023-10-31 泽兰德制药公司 细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用
CN110944719A (zh) * 2017-07-25 2020-03-31 合帕吉恩治疗公司 凋亡蛋白的二聚肽抑制剂
EP3658158A4 (en) * 2017-07-27 2021-04-14 The National Institute for Biotechnology in the Negev Ltd. SMAC / YLDIABLO INHIBITORS TO TREAT CANCER
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのe3ユビキチンリガーゼ結合活性を有するキメラ(protac)化合物を標的とし、アルファ-シヌクレインタンパク質を標的とするタンパク質分解
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2022056368A1 (en) 2020-09-14 2022-03-17 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of estrogen receptor
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
WO2025256500A1 (zh) * 2024-06-11 2025-12-18 温州玮祎康泽生物科技有限公司 Xiap e3连接酶作为肿瘤治疗靶点及其靶向化合物的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801012A (en) * 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
AU7473500A (en) * 1999-09-01 2001-03-26 University Of Pittsburgh Identification of peptides that facilitate uptake and cytoplasmic and/or nucleartransport of proteins, dna and viruses
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002030959A2 (en) * 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
DE10105041A1 (de) * 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten

Similar Documents

Publication Publication Date Title
JP2006501181A5 (https=)
RU92004336A (ru) Водорастворимые производные камптотецина, способ их получения, фармацевтическая композиция, способ ингибирования энзима топоизомеразы, промежуточные продукты
ME00876B (me) 4"supstituisani-9-deokso-9a-aza-9a-homoeritromicin a derivati
ATE126216T1 (de) Pyrazolderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung.
IL51297A (en) Proline derivatives and related compounds pharmaceutical compositions containing the same and process for the preparation thereof
CA2401502A1 (en) Carboxylic acid derivatives as ip antagonists
SE7614258L (sv) Forfarande for framstellning av kinazoloderivat
NO156690C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive indanderivater.
SE9703377D0 (sv) New compounds
PT992509E (pt) Novos derivados macrolidos
DE60105610D1 (en) Pyrazinonderivate
ATE239711T1 (de) Neue allythiopyridazinderivate und verfahren zu ihrer herstellung
KR940011450A (ko) 살진균성 2-알콕시-2-이미다졸린-5-온 유도체
RU2004102398A (ru) Производные бензо[g]хинолина для лечения глаукомы и близорукости
DE60202682D1 (de) Chinoline derivate und ihre anwendung als antitumor agentien
ATE445589T1 (de) Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält
JP2026503618A5 (https=)
SE8007025L (sv) Derivat av 1,2,4-oxadiazolin-5-on, sett for deras framstellning och farmaceutiska beredningar innehallande dem
RU2001104880A (ru) Пиперазиновые производные, обладающие антидиабетической активностью, способы их получения и содержащие их композиции
FR2793246B1 (fr) Nouveaux derives de 1-aza-2-alkyl-6-aryl-cycloalcanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NO150316C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive nitrosoureaderivater
KR940005621A (ko) 벤조[b]티오펜-3-일-피페라진. 이의 제조방법 및 약제로서 이의 용도
SE8500964L (sv) Aminodiarylsulfoxidderivat, forfarande for framstellning derav och farmaceutiska och pesticidiska kompositioner innehallande desamma
RU2005124286A (ru) Производное олигосахаридов
JP2008543941A (ja) アンサマイシン製剤およびその使用方法